ProCE Banner Activity

Targeting BCMA in Myeloma With Antibody–Drug Conjugates and Bispecific Agents

Clinical Thought
Natalie S. Callander, MD, reviews new and emerging treatment strategies with antibody–drug conjugates and bispecific antibodies and T-cell engagers targeting BCMA in patients with heavily pretreated relapsed/refractory multiple myeloma.

Released: November 12, 2020

Expiration: November 11, 2021

No longer available for credit.

Share

Faculty

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Celgene

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has disclosed that she has received funds for research support from Cellectar.